<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37373215</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Decipher the Immunopathological Mechanisms and Set Up Potential Therapeutic Strategies for Patients with Lupus Nephritis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10066</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241210066</ELocationID><Abstract><AbstractText>Lupus nephritis (LN) is one of the most severe complications in patients with systemic lupus erythematosus (SLE). Traditionally, LN is regarded as an immune complex (IC) deposition disease led by dsDNA-anti-dsDNA-complement interactions in the subendothelial and/or subepithelial basement membrane of glomeruli to cause inflammation. The activated complements in the IC act as chemoattractants to chemically attract both innate and adaptive immune cells to the kidney tissues, causing inflammatory reactions. However, recent investigations have unveiled that not only the infiltrating immune-related cells, but resident kidney cells, including glomerular mesangial cells, podocytes, macrophage-like cells, tubular epithelial cells and endothelial cells, may also actively participate in the inflammatory and immunological reactions in the kidney. Furthermore, the adaptive immune cells that are infiltrated are genetically restricted to autoimmune predilection. The autoantibodies commonly found in SLE, including anti-dsDNA, are cross-reacting with not only a broad spectrum of chromatin substances, but also extracellular matrix components, including &#x3b1;-actinin, annexin II, laminin, collagen III and IV, and heparan sulfate proteoglycan. Besides, the glycosylation on the Fab portion of IgG anti-dsDNA antibodies can also affect the pathogenic properties of the autoantibodies in that &#x3b1;-2,6-sialylation alleviates, whereas fucosylation aggravates their nephritogenic activity. Some of the coexisting autoantibodies, including anti-cardiolipin, anti-C1q, anti-ribosomal P autoantibodies, may also enhance the pathogenic role of anti-dsDNA antibodies. In clinical practice, the identification of useful biomarkers for diagnosing, monitoring, and following up on LN is quite important for its treatments. The development of a more specific therapeutic strategy to target the pathogenic factors of LN is also critical. We will discuss these issues in detail in the present article.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Chang-Youh</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0000-0002-4154-4018</Identifier><AffiliationInfo><Affiliation>Division of Immunology &amp; Rheumatology, Department of Medicine, Fu Jen Catholic University Hospital &amp; College of Medicine, Fu Jen Catholic University, New Taipei City 24352, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ko-Jen</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0002-4544-4620</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Immunology &amp; Allergy, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 106319, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Chieh-Yu</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0000-0002-3218-0689</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Immunology &amp; Allergy, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 106319, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Cheng-Hsun</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Immunology &amp; Allergy, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 106319, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hui-Ting</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>MacKay Memorial Hospital &amp; MacKay Medical College, New Taipei City 25245, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Tsai-Hung</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital and Faculty of Medicine, National Yang-Ming Chiao-Tung University, Taipei 112304, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Yee-Yung</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Department of Medicine, Fu Jen Catholic University Hospital &amp; College of Medicine, Fu Jen Catholic University, New Taipei City 24352, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsao</LastName><ForeName>Yen-Po</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Division of Holistic and Multidisciplinary Medicine, Department of Medicine, Taipei Veterans General Hospital and Faculty of Medicine, National Yang-Ming Chiao-Tung University, Taipei 112304, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Song-Chou</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Immunology &amp; Allergy, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 106319, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chia-Li</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Immunology &amp; Allergy, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 106319, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FJUH11220</GrantID><Agency>Fu Jen Catholic University Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007678" MajorTopicYN="N">Kidney Glomerulus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NLRP3 inflammasome</Keyword><Keyword MajorTopicYN="N">anti-dsDNA antibodies</Keyword><Keyword MajorTopicYN="N">cross-reactivity</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">renal resident cells</Keyword><Keyword MajorTopicYN="N">type I interferon</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37373215</ArticleId><ArticleId IdType="pmc">PMC10298725</ArticleId><ArticleId IdType="doi">10.3390/ijms241210066</ArticleId><ArticleId IdType="pii">ijms241210066</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hoover P.J., Costenbader K.H. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist&#x2019;s perspective. Kidney Int. 2016;90:487&#x2013;492. doi: 10.1016/j.kint.2016.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2016.03.042</ArticleId><ArticleId IdType="pmc">PMC5679458</ArticleId><ArticleId IdType="pubmed">27344205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly J.G., O&#x2019;Keeffe A.G., Su L., Urowitz M.B., Romero-Diaz J., Gordon C., Bae S.-C., Bernatsky S., Clarke A.E., Wallace D.J., et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology. 2016;55:252&#x2013;262. doi: 10.1093/rheumatology/kev311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev311</ArticleId><ArticleId IdType="pmc">PMC4939728</ArticleId><ArticleId IdType="pubmed">26342222</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening J.J., D&#x2019;Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., Balow J.E., Bruijn J.A., Cook T., Ferrario F., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521&#x2013;530. doi: 10.1111/j.1523-1755.2004.00443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G., Depetri F., Ponticelli C. Lupus nephritis: When and how often to biopsy and what does it mean? J. Autoimmun. 2016;74:27&#x2013;40. doi: 10.1016/j.jaut.2016.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.06.006</ArticleId><ArticleId IdType="pubmed">27349351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastian H.M., Roseman J.M., McGwin G., Jr., Alarc&#xf3;n G.S., Friedman A.W., Fessler B.J., Baethge B.A., Reveille J.D., LUMINA Study Group Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11:152&#x2013;160. doi: 10.1191/0961203302lu158oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203302lu158oa</ArticleId><ArticleId IdType="pubmed">12004788</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria A., Iaccarino L., Ghirardello A., Zampieri S., Arienti S., Sarzi-Puttini P., Atzeni F., Piccoli A., Todesco S. Long-term prognosis and causes of death in systemic lupus erythematosus. Am. J. Med. 2006;119:700&#x2013;706. doi: 10.1016/j.amjmed.2005.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2005.11.034</ArticleId><ArticleId IdType="pubmed">16887417</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders H.-J., Saxena R., Zhao M.-H., Parodis I., Salmon J.E., Mohan C. Lupus nephritis. Nat. Rev. Dis. Primers. 2020;6:7. doi: 10.1038/s41572-019-0141-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S., Cozzi M., Barinotti A., Radin M., Cecchi I., Fenoglio R., Mancardi D., Jones G.W., Rossi D., Roccatello D. Renal fibrosis in lupus nephritis. Int. J. Mol. Sci. 2022;23:14317. doi: 10.3390/ijms232214317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232214317</ArticleId><ArticleId IdType="pmc">PMC9699516</ArticleId><ArticleId IdType="pubmed">36430794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparotto M., Gatto M., Binda V., Doria A., Moroni G. Lupus nephritis: Clinical presentations and outcomes in the 21st century. Rheumatology. 2020;59((Suppl. S5)):v39&#x2013;v51. doi: 10.1093/rheumatology/keaa381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa381</ArticleId><ArticleId IdType="pmc">PMC7751166</ArticleId><ArticleId IdType="pubmed">33280015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C., Li P., Dang X., Zhang X., Mao Y., Chen X. Lupus nephritis: New progress in diagnosis and treatment. J. Autommun. 2022;132:102871. doi: 10.1016/j.jaut.2022.102871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102871</ArticleId><ArticleId IdType="pubmed">35999111</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Fueyo A., Bradley S.J., Klatzmann D., Tsokos G.C. T cells and autoimmune kidney disease. Nat. Rev. Nephrol. 2017;13:329&#x2013;343. doi: 10.1038/nrneph.2017.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.34</ArticleId><ArticleId IdType="pubmed">28287110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat P., Radhakrishnan J. B lymphocytes and lupus nephritis: New insights into pathogenesis and targeted therapies. Kidney Int. 2008;73:261&#x2013;268. doi: 10.1038/sj.ki.5002663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5002663</ArticleId><ArticleId IdType="pubmed">18004299</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A., Henderson S.G., Brandt D., Liu N., Guttikonda R., Hsieh C., Kaverina N., Utset T.O., Meehan S.M., Quigg R.J., et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 2011;186:1849&#x2013;1860. doi: 10.4049/jimmunol.1001983.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001983</ArticleId><ArticleId IdType="pmc">PMC3124090</ArticleId><ArticleId IdType="pubmed">21187439</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M., Yagita H., Inoue H., Takanashi T., Matsuda H., Munechika E., Kanamaru Y., Shirato I., Tomino Y., Matsushima K., et al. Selective accumulation of CCR4+ T lymphocytes into renal tissue of patients with lupus nephritis. Arthritis Rheum. 2002;46:735&#x2013;740. doi: 10.1002/art.10112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10112</ArticleId><ArticleId IdType="pubmed">11920409</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata H., Matsumura R., Koyama A., Sugiyama T., Sueishi M., Shibuya K., Tsutsumi A., Sumida T. T cell receptor repertoire of T cells in the kidneys of patients with lupus nephritis. Arthritis Rheum. 2002;46:2141&#x2013;2147. doi: 10.1002/art.10432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10432</ArticleId><ArticleId IdType="pubmed">12209519</ArticleId></ArticleIdList></Reference><Reference><Citation>Crispin J.C., Oukka M., Bayliss G., Cohen R.A., Van Beek C.A., Stillman I.E., Kyttaris V.C., Juang Y.-T., Tsokos G.C. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 2008;181:8761&#x2013;8766. doi: 10.4049/jimmunol.181.12.8761.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.12.8761</ArticleId><ArticleId IdType="pmc">PMC2596652</ArticleId><ArticleId IdType="pubmed">19050297</ArticleId></ArticleIdList></Reference><Reference><Citation>Enghard P., Humrich J.Y., Rudolph B., Rosenberger S., Biesen R., Kuhn A., Manz R., Hiepe F., Radbruch A., Burmester G.-R., et al. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum. 2009;60:199&#x2013;206. doi: 10.1002/art.24136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24136</ArticleId><ArticleId IdType="pubmed">19116922</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison S.J. Breaches in the Bowman&#x2019;s capsule and CD8+ T cell infiltration in crescentic GN. Nat. Rev. Nephrol. 2018;14:597. doi: 10.1038/s41581-018-0046-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-018-0046-y</ArticleId><ArticleId IdType="pubmed">30042436</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro D.A.D., Hughes J. The origins and functions of tissue-resident macrophages in kidney development. Front. Physiol. 2017;8:837. doi: 10.3389/fphys.2017.00837.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00837</ArticleId><ArticleId IdType="pmc">PMC5660965</ArticleId><ArticleId IdType="pubmed">29118719</ArticleId></ArticleIdList></Reference><Reference><Citation>Der E., Suryawanshi H., Morozov P., Kustagi M., Goilav B., Ranabothu S., Izmirly P., Clancy R., Belmont H.M., Koenigsberg M., et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat. Immunol. 2019;20:915&#x2013;927. doi: 10.1038/s41590-019-0386-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0386-1</ArticleId><ArticleId IdType="pmc">PMC6584054</ArticleId><ArticleId IdType="pubmed">31110316</ArticleId></ArticleIdList></Reference><Reference><Citation>Arazi A., Rao D.A., Berthier C.C., Davidson A., Liu Y., Hoover P.J., Chicoine A., Eisenhaure T.M., Jonsson A.H., Li S., et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 2019;20:902&#x2013;914. doi: 10.1038/s41590-019-0398-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0398-x</ArticleId><ArticleId IdType="pmc">PMC6726437</ArticleId><ArticleId IdType="pubmed">31209404</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A. Renal mononuclear phagocytes in lupus nephritis. ACR Open Rheumatol. 2021;3:442&#x2013;450. doi: 10.1002/acr2.11269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11269</ArticleId><ArticleId IdType="pmc">PMC8280821</ArticleId><ArticleId IdType="pubmed">34060247</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos E., Seron D., Hartley R.B., Cameron J.S. Lupus nephritis: Correlation of interstitial cells with glomerular function. Kidney Int. 1990;37:100&#x2013;169. doi: 10.1038/ki.1990.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1990.14</ArticleId><ArticleId IdType="pubmed">1967662</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agati V.D., Appel G.B., Estes D., Knowles D.M., II, Pirani C.L. Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int. 1986;30:573&#x2013;581. doi: 10.1038/ki.1986.223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1986.223</ArticleId><ArticleId IdType="pubmed">3537453</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto S., Nakatani K., Iwano M., Asai O., Samejima K.-i., Sakan H., Terada M., Harada K., Akai Y., Shiiki H., et al. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am. J. Kidney Dis. 2007;50:47&#x2013;58. doi: 10.1053/j.ajkd.2007.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2007.04.012</ArticleId><ArticleId IdType="pubmed">17591524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatani K., Yoshimoto S., Iwano M., Asai O., Samejima K.-i., Sakan H., Terada M., Hasegawa H., Nose M., Saito Y. Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: Association with their severity and diversity in lupus models. Am. J. Physiol. Renal Physiol. 2010;299:F207&#x2013;F216. doi: 10.1152/ajprenal.00482.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00482.2009</ArticleId><ArticleId IdType="pubmed">20410215</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C., Chang A., Brandt D., Guttikonda R., Utset T.O., Clark M.R. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res. 2011;63:865&#x2013;874. doi: 10.1002/acr.20441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20441</ArticleId><ArticleId IdType="pmc">PMC3106120</ArticleId><ArticleId IdType="pubmed">21309006</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294:1540&#x2013;1543. doi: 10.1126/science.1064890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1064890</ArticleId><ArticleId IdType="pubmed">11711679</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinecker C., Zw&#xf6;lfer B., K&#xf6;ller M., M&#xe4;nner G., Smolen J.S. Alterations of dendritic cells in systemic lupus erythematosus: Phenotypic and functional deficiencies. Arthritis Rheum. 2001;44:856&#x2013;865. doi: 10.1002/1529-0131(200104)44:4&lt;856::AID-ANR142&gt;3.0.CO;2-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200104)44:4&lt;856::AID-ANR142&gt;3.0.CO;2-A</ArticleId><ArticleId IdType="pubmed">11315925</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucci M., Quatraro C., Lombardi L., Pellegrino C., Dammacco F., Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: Role of interleukin-18. Arthritis Rheum. 2008;58:251&#x2013;262. doi: 10.1002/art.23186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23186</ArticleId><ArticleId IdType="pubmed">18163476</ArticleId></ArticleIdList></Reference><Reference><Citation>Maria N.I., Davidson A. Renal macrophages and dendritic cells in SLE nephritis. Curr. Rheumatol. Rep. 2017;19:81. doi: 10.1007/s11926-017-0708-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-017-0708-y</ArticleId><ArticleId IdType="pubmed">29119288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Tang W., Tang W. Immune cell infiltration characteristics and related core genes in lupus nephritis: Results from bioinformatic analysis. BMC Immunol. 2019;20:37. doi: 10.1186/s12865-019-0316-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-019-0316-x</ArticleId><ArticleId IdType="pmc">PMC6805654</ArticleId><ArticleId IdType="pubmed">31638917</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L., Conti S., Benigni A., Remuzzi G. Podocyte actin dynamics in health and disease. Nat. Rev. Nephrol. 2016;12:692&#x2013;710. doi: 10.1038/nrneph.2016.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.127</ArticleId><ArticleId IdType="pubmed">27573725</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroemer G. Autophagy: A druggable process that is deregulated in aging and human disease. J. Clin. Investig. 2015;125:1&#x2013;4. doi: 10.1172/JCI78652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI78652</ArticleId><ArticleId IdType="pmc">PMC4382251</ArticleId><ArticleId IdType="pubmed">25654544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069&#x2013;1075. doi: 10.1038/nature06639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06639</ArticleId><ArticleId IdType="pmc">PMC2670399</ArticleId><ArticleId IdType="pubmed">18305538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X.-J., Klionsky D.J., Zhang H. Podocytes and autophagy: A potential therapeutic target in lupus nephritis. Autophagy. 2019;15:908&#x2013;912. doi: 10.1080/15548627.2019.1580512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1580512</ArticleId><ArticleId IdType="pmc">PMC6526813</ArticleId><ArticleId IdType="pubmed">30755075</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J., Ye M., Zhao L., Zou W., Shen W., Zhang H., Gong J., He Q. The novel involvement of podocyte autophagic activity in the pathogenesis of lupus nephritis. Histol. Histopathol. 2018;33:803&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">29446059</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva-Damaso N., Payan J., Oliva-Damaso E., Pereda T., Bomback A.S. Lupus podocytopathy: An overview. Adv. Chronic Kidney Dis. 2019;26:369&#x2013;375. doi: 10.1053/j.ackd.2019.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ackd.2019.08.011</ArticleId><ArticleId IdType="pmc">PMC8405037</ArticleId><ArticleId IdType="pubmed">31733721</ArticleId></ArticleIdList></Reference><Reference><Citation>Avraham S., Korin B., Chung J.-J., Oxburgh L., Shaw A.S. The mesangial cell-the glomerular stromal cell. Nat. Rev. Nephrol. 2021;17:855&#x2013;864. doi: 10.1038/s41581-021-00474-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-021-00474-8</ArticleId><ArticleId IdType="pubmed">34508249</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Zhang L., Wang Y., Hu W., Wang C., Wen Z. Mesangial cell: A hub in lupus nephritis. Front. Immunol. 2022;13:1063497. doi: 10.3389/fimmu.2022.1063497.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1063497</ArticleId><ArticleId IdType="pmc">PMC9795068</ArticleId><ArticleId IdType="pubmed">36591251</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.-L., Sun K.-H., Tsai C.-Y., Hsieh S.-C., Yu H.-S. Anti-dsDNA antibody up-regulates interleukin 6, but not cyclo-oxygenase, gene expression in glomerular mesangial cells: A marker of immune-mediated renal damage? Inflamm. Res. 2001;50:12&#x2013;18. doi: 10.1007/s000110050718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s000110050718</ArticleId><ArticleId IdType="pubmed">11235016</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowling T.K. Mesangial cells in lupus nephritis. Curr. Rheumatol. Rep. 2022;23:83. doi: 10.1007/s11926-021-01048-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01048-0</ArticleId><ArticleId IdType="pubmed">34985599</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok S.-K., Tsokos G.C. New insights into the role of renal resident cells in the pathogenesis of lupus nephritis. Korean J. Intern. Med. 2018;33:284&#x2013;289. doi: 10.3904/kjim.2017.383.</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2017.383</ArticleId><ArticleId IdType="pmc">PMC5840601</ArticleId><ArticleId IdType="pubmed">29320847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolios A.G., Tsokos G.C. Skin-kidney crosstalk in SLE. Nat. Rev. Rheumatol. 2021;17:253&#x2013;254. doi: 10.1038/s41584-021-00588-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00588-0</ArticleId><ArticleId IdType="pubmed">33633360</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung S.-S.J., Fu S.M. Interactions among glomerulus infiltrating macrophages and intrinsic cells via cytokines in chronic lupus glomerulonephritis. J. Autoimmun. 2020;106:102331. doi: 10.1016/j.jaut.2019.102331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102331</ArticleId><ArticleId IdType="pmc">PMC6930355</ArticleId><ArticleId IdType="pubmed">31495649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargava R., Li H., Tsokos G.C. Pathogenesis of lupus nephritis: The contribution of immune and kidney resident cells. Curr. Opin. Rheumatol. 2023;35:107&#x2013;116. doi: 10.1097/BOR.0000000000000887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000887</ArticleId><ArticleId IdType="pubmed">35797522</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaly S., Rakaee M., Abdi R., Tsokos G.C., Fenton K.A. Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis. Autoimmun. Rev. 2021;20:102980. doi: 10.1016/j.autrev.2021.102980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102980</ArticleId><ArticleId IdType="pubmed">34718163</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorraji S.E., Kanapathippillai P., Hovd A.-M.K., Stenersr&#xf8;d M.R., Horvei K.D., Ursvik A., Figenschau S.L., Thiyagarajan D., Fenton C.G., Pedersen H.L., et al. Kidney tertiary lymphoid structures in lupus nephritis develop into large interconnected networks and resemble lymph nodes in gene signature. Am. J. Pathol. 2020;190:2203&#x2013;2225. doi: 10.1016/j.ajpath.2020.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.07.015</ArticleId><ArticleId IdType="pubmed">32818496</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhfakh R., Zian Z., Elloumi N., Abida O., Bouallegui E., Houssaini H., Volpe E., Capone A., Hachicha H., Marzouk S., et al. Th17 and Th1 cells in systemic lupus erythematosus with focus on lupus nephritis. Immunol. Res. 2022;70:644&#x2013;653. doi: 10.1007/s12026-022-09296-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-022-09296-7</ArticleId><ArticleId IdType="pubmed">35666434</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisitkun P., Ha H.-L., Wang H., Claudio E., Tivy C.C., Zhou H., Mayadas T.N., Illei G.G., Siebenlist U. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity. 2012;37:1104&#x2013;1115. doi: 10.1016/j.immuni.2012.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.08.014</ArticleId><ArticleId IdType="pmc">PMC3594848</ArticleId><ArticleId IdType="pubmed">23123062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 2009;183:3160&#x2013;3169. doi: 10.4049/jimmunol.0900385.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900385</ArticleId><ArticleId IdType="pmc">PMC2766304</ArticleId><ArticleId IdType="pubmed">19657089</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Adamopoulos I.E., Moulton V.R., Stillman I.E., Herbert Z., Moon J.J., Sharabi A., Krishfield S., Tsokos M.G., Tsokos G.C. Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells. Nat. Commun. 2020;11:2859. doi: 10.1038/s41467-020-16636-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16636-4</ArticleId><ArticleId IdType="pmc">PMC7275084</ArticleId><ArticleId IdType="pubmed">32503973</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A., Lee K., D&#x2019;Agati V.D., Wei C., Fu J., Guan T.-J., He J.C., Schlondorff D., Agudo J. Bowman&#x2019;s capsule provides a protective niche for podocytes from cytotoxic CD8+ T cells. J. Clin. Investig. 2018;128:3413&#x2013;3424. doi: 10.1172/JCI97879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI97879</ArticleId><ArticleId IdType="pmc">PMC6063505</ArticleId><ArticleId IdType="pubmed">29985168</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Tsokos M.G., Bhargava R., Adamopoulos I.E., Menn-Josephy H., Stillman I.E., Rosenstiel P., Jordan J., Tsokos G.C. IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. J. Clin. Investig. 2021;131:e142428. doi: 10.1172/JCI142428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI142428</ArticleId><ArticleId IdType="pmc">PMC8203450</ArticleId><ArticleId IdType="pubmed">33956666</ArticleId></ArticleIdList></Reference><Reference><Citation>Teramoto K., Negoro N., Kitamoto K., Iwai T., Iwao H., Okamura M., Miura K. Microarray analysis of glomerular gene expression in murine lupus nephritis. J. Pharmacol. Sci. 2008;106:56&#x2013;57. doi: 10.1254/jphs.FP0071337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jphs.FP0071337</ArticleId><ArticleId IdType="pubmed">18187931</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz O.M., Turner J.-E., Paust H.-J., Lindner M., Peters A., Heiss K., Velden J., Hopfer H., Fehr S., Krieger T., et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J. Immunol. 2009;183:4693&#x2013;4704. doi: 10.4049/jimmunol.0802626.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0802626</ArticleId><ArticleId IdType="pubmed">19734217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tshilela K.A., Ikeuchi H., Matsumoto T., Kuroiwa T., Sakurai N., Sakairi T., Kaneko Y., Maeshima A., Hiromura K., Nojima Y. Glomerular cytokine expression in murine lupus nephritis. Clin. Exp. Nephrol. 2016;20:23&#x2013;29. doi: 10.1007/s10157-015-1123-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-015-1123-1</ArticleId><ArticleId IdType="pubmed">25985839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.-Y., Wu T.-H., Huang S.-F., Sun K.-H., Hsieh S.-C., Han S.-H., Yu H.-S., Yu C.-L. Abnormal thymic and splenic IL-4 and TNF-&#x3b1; expression in MRL-lpr/lpr mice. Scand. J. Immunol. 1995;41:157&#x2013;163. doi: 10.1111/j.1365-3083.1995.tb03548.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1995.tb03548.x</ArticleId><ArticleId IdType="pubmed">7863262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.-T., Shiao Y.-M., Wu T.-H., Chen W.-S., Hsu Y.-H., Tsai S.-F., Tsai C.-Y. Serum BLC/CXCL13 concentration and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J. Rheumatol. 2010;37:45&#x2013;52. doi: 10.3899/jrheum.090450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.090450</ArticleId><ArticleId IdType="pubmed">19955043</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Ito S., Chino Y., Goto D., Matsumoto I., Murata H., Tsutsumi A., Hayashi T., Uchida K., Usui J., et al. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin. Exp. Immunol. 2010;159:1&#x2013;10. doi: 10.1111/j.1365-2249.2009.04031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2009.04031.x</ArticleId><ArticleId IdType="pmc">PMC2802690</ArticleId><ArticleId IdType="pubmed">19807734</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S., Cheung K.F., Zhang Q., Chan T.M. Mediators of inflammation and their effect on resident renal cells: Implications in lupus nephritis. Clin. Dev. Immunol. 2013;2013:317682. doi: 10.1155/2013/317682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/317682</ArticleId><ArticleId IdType="pmc">PMC3793320</ArticleId><ArticleId IdType="pubmed">24171032</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquissi F.C., Absensur H. The Th17/IL-17 axis and kidney disease, with focus on lupus nephritis. Front. Med. 2021;8:654912. doi: 10.3389/fmed.2021.654912.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.654912</ArticleId><ArticleId IdType="pmc">PMC8446428</ArticleId><ArticleId IdType="pubmed">34540858</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F., Burns K., Tschopp J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell. 2002;10:417&#x2013;426. doi: 10.1016/S1097-2765(02)00599-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(02)00599-3</ArticleId><ArticleId IdType="pubmed">12191486</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley N., Jeltema D., Duan Y., He Y. The NLRP3 inflamasome: An overview of mechanism of activation and regulation. Int. J. Mol. Sci. 2019;20:3328. doi: 10.3390/ijms20133328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133328</ArticleId><ArticleId IdType="pmc">PMC6651423</ArticleId><ArticleId IdType="pubmed">31284572</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigeoka A.A., Mueller J.L., Kambo A., Mathison J.C., King A.J., Hall W.F., da Silva Correia J., Ulevitch R.J., Hoffman H.M., Mckay D.B. An inflammasome-independent role for epithelial-expressed NLRP3 in renal ischemia-reperfusion injury. J. Immunol. 2010;185:6277&#x2013;6285. doi: 10.4049/jimmunol.1002330.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002330</ArticleId><ArticleId IdType="pmc">PMC3020135</ArticleId><ArticleId IdType="pubmed">20962258</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz G., Darisipudi M.N., Anders H.-J. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol. Dial. Transplant. 2014;29:41&#x2013;48. doi: 10.1093/ndt/gft332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gft332</ArticleId><ArticleId IdType="pubmed">24026244</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira C.B., Lima C.A.D., Vajgel G., Sandrin-Garcia P. The role of NLRP3 inflammasome in lupus nephritis. Int. J. Mol. Sci. 2021;22:12476. doi: 10.3390/ijms222212476.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212476</ArticleId><ArticleId IdType="pmc">PMC8625721</ArticleId><ArticleId IdType="pubmed">34830358</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton-Pampols P., Diaz-Requena C., Martinez-Valenzuela L., Gomez-Preciado F., Fulladosa X., Vidal-Alabro A., Torras J., Lloberas N., Draibe J. The role of inflammasomes in glomerulonephritis. Int. J. Mol. Sci. 2022;23:4208. doi: 10.3390/ijms23084208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23084208</ArticleId><ArticleId IdType="pmc">PMC9029880</ArticleId><ArticleId IdType="pubmed">35457026</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C., Fu R., Zhou M., Wang S., Huang Y., Hu H., Zhao J., Gaskin F., Yang N., Fu S.M. Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation. J. Autoimmun. 2019;103:112286. doi: 10.1016/j.jaut.2019.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.05.014</ArticleId><ArticleId IdType="pmc">PMC6708470</ArticleId><ArticleId IdType="pubmed">31133359</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu R., Guo C., Wang S., Huang Y., Jin O., Hu H., Chen J., Xu B., Zhou M., Zhao J., et al. Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol. 2017;69:1636&#x2013;1646. doi: 10.1002/art.40155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40155</ArticleId><ArticleId IdType="pmc">PMC5568813</ArticleId><ArticleId IdType="pubmed">28544564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D.-W., Shao J., Lin J., Zhang N., Lu B.-J., Lin S.-C., Dong M.-Q., Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325:332&#x2013;336. doi: 10.1126/science.1172308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1172308</ArticleId><ArticleId IdType="pubmed">19498109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv F., He Y., Xu H., Li Y., Han L., Yan L., Lang H., Zhao Y., Zhao Z., Qi Y. CD36 aggravates podocyte injury by activating NLRP3 inflammasome and inhibiting autophagy in lupus nephritis. Cell Death Dis. 2022;13:729. doi: 10.1038/s41419-022-05179-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-05179-9</ArticleId><ArticleId IdType="pmc">PMC9399182</ArticleId><ArticleId IdType="pubmed">35999224</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao Y.-P., Tseng F.-Y., Chao C.-W., Chen M.-H., Yeh Y.-C., Abdulkareem B.O., Chen S.-Y., Chuang W.-T., Chang P.-C., Chen I.-C., et al. NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression. J. Clin. Investig. 2023;133:e157272. doi: 10.1172/JCI157272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI157272</ArticleId><ArticleId IdType="pmc">PMC10145918</ArticleId><ArticleId IdType="pubmed">37115700</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N., Harada T., Mizushima Y., Sakane T. Possible pathogenic role of cationic anti-DNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus. J. Immunol. 1993;151:1128&#x2013;1136. doi: 10.4049/jimmunol.151.2.1128.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.151.2.1128</ArticleId><ArticleId IdType="pubmed">8335894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostoslavsky G., Fischel R., Yachimovich N., Yarkoni Y., Rosenmann E., Monestier M., Baniyash M., Eilat D. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: A case for tissue injury by molecular mimicry. Eur. J. Immunol. 2001;31:1221&#x2013;1227. doi: 10.1002/1521-4141(200104)31:4&lt;1221::AID-IMMU1221&gt;3.0.CO;2-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-4141(200104)31:4&lt;1221::AID-IMMU1221&gt;3.0.CO;2-P</ArticleId><ArticleId IdType="pubmed">11298348</ArticleId></ArticleIdList></Reference><Reference><Citation>Deocharan B., Qing X., Lichauco J., Putterman C. Alpha-actinin is cross reactive renal target for pathogenic anti-DNA antibodies. J. Immunol. 2002;168:3072&#x2013;3078. doi: 10.4049/jimmunol.168.6.3072.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.6.3072</ArticleId><ArticleId IdType="pubmed">11884481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S., Cheung K.F., Zhang Q., Chan T.M. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J. Am. Soc. Nephrol. 2010;21:1912&#x2013;1927. doi: 10.1681/ASN.2009080805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2009080805</ArticleId><ArticleId IdType="pmc">PMC3014006</ArticleId><ArticleId IdType="pubmed">20847146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Cheng H., Zhang Y., Fang C., Xia Y. The antigen-binding fragment of anti-double-stranded DNA IgG enhances F-actin formation in mesangial cells by binding to alpha-actinin-4. Exp. Biol. Med. 2012;237:1023&#x2013;1031. doi: 10.1258/ebm.2012.012033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ebm.2012.012033</ArticleId><ArticleId IdType="pubmed">22929799</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchin G., Son M., Kim S.J., Ben-Zvi I., Zhang J., Diamond B. Anti-DNA antibodies cross-react with C1q. J. Autoimmun. 2013;44:34&#x2013;39. doi: 10.1016/j.jaut.2013.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2013.06.002</ArticleId><ArticleId IdType="pmc">PMC3871866</ArticleId><ArticleId IdType="pubmed">23834843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.L., Huang M.H., Tsai C.Y., Tsai Y.Y., Tsai S.T., Sun K.H., Han S.H., Yu H.S. The effect of human polyclonal anti-dsDNA autoantibodies on apoptotic gene expression in cultured rat glomerular mesangial cells. Scand. J. Rheumatol. 1998;27:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506879</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S., Tsang R.C.W., Leung J.K.H., Chan T.M. Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1beta. Kidney Int. 2006;69:272&#x2013;280. doi: 10.1038/sj.ki.5000042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5000042</ArticleId><ArticleId IdType="pubmed">16408116</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing X., Zavadil J., Crosby M.B., Hogarth M.P., Hahn B.H., Mohan C., Gilkeson G.S., Bottinger E.P., Putterman C. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum. 2006;54:2198&#x2013;2210. doi: 10.1002/art.21934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21934</ArticleId><ArticleId IdType="pubmed">16804897</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing X., Pitashny M., Thomas D.B., Barrat F.J., Hogarth M.P., Putterman C. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: Involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol. Lett. 2008;121:61&#x2013;73. doi: 10.1016/j.imlet.2008.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2008.08.007</ArticleId><ArticleId IdType="pmc">PMC2677706</ArticleId><ArticleId IdType="pubmed">18822317</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S., Zhang Q., Zhang C.Z., Chan K.W., Lui S.L., Chan T.M. Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis Rheum. 2009;60:2071&#x2013;2082. doi: 10.1002/art.24573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24573</ArticleId><ArticleId IdType="pubmed">19565476</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zhao C., Wang S., Huang Y., Wang H., Zhao J., Yang N. Anti-dsDNA antibodies induce inflammation via endoplasmic reticulum stress in human mesangial cells. J. Transl. Med. 2015;13:178. doi: 10.1186/s12967-015-0536-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-015-0536-7</ArticleId><ArticleId IdType="pmc">PMC4467615</ArticleId><ArticleId IdType="pubmed">26040555</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S., Ng C.Y.C., Ho S.K., Cheung K.F., Chan K.W., Zhang Q., Chau M.K.M., Chan T.M. Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-&#x3b2;1 and collagen synthesis. J. Autoimmun. 2015;58:111&#x2013;122. doi: 10.1016/j.jaut.2015.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.01.008</ArticleId><ArticleId IdType="pubmed">25666976</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S., Chan T.M. Anti-dsDNA antibodies and resident renal cells&#x2014;Their putative roles in pathogenesis of renal lesions in lupus nephritis. Clin. Immunol. 2017;185:40&#x2013;50. doi: 10.1016/j.clim.2016.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.09.002</ArticleId><ArticleId IdType="pubmed">27612436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z., Leppla S.H., Li B., Elkins C.A. Antibodies specific for nucleic acids and applications in genomic detection and clinical diagnostics. Expert Rev. Mol. Diagn. 2014;14:895&#x2013;916. doi: 10.1586/14737159.2014.931810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737159.2014.931810</ArticleId><ArticleId IdType="pubmed">25014728</ArticleId></ArticleIdList></Reference><Reference><Citation>Akberova N.I., Zhmurov A.A., Nevzorova T.A., Litvinov R.I. An anti-DNA antibody prefers damaged dsDNA over native. J. Biomol. Struct. Dyn. 2017;35:219&#x2013;232. doi: 10.1080/07391102.2015.1128979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2015.1128979</ArticleId><ArticleId IdType="pubmed">26646388</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Xia Y. Anti-double stranded DNA antibodies: Origin, pathogenicity, and targeted therapies. Front. Immunol. 2019;10:1667. doi: 10.3389/fimmu.2019.01667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01667</ArticleId><ArticleId IdType="pmc">PMC6650533</ArticleId><ArticleId IdType="pubmed">31379858</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S., Chan T.M. Mechanisms of kidney injury in lupus nephritis&#x2014;The role of anti-dsDNA antibodies. Front. Immunol. 2015;6:475. doi: 10.3389/fimmu.2015.00475.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00475</ArticleId><ArticleId IdType="pmc">PMC4569852</ArticleId><ArticleId IdType="pubmed">26441980</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K.-H., Lui W.-T., Tsai C.-Y., Tang S.-J., Han S.H., Yu C.-L. Anti-dsDNA antibodies cross-react with ribosomal P proteins expressed on the surface of glomerular mesangial cells to exert a cytostatic effect. Immunology. 1995;85:262&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383890</ArticleId><ArticleId IdType="pubmed">7642215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K.-H., Liu W.-T., Tang S.-J., Tsai C.-Y., Hsieh S.-C., Wu T.-H., Han S.-H., Yu C.-L. The expression of acidic ribosomal phosphoproteins on the surface membrane of different tissues in autoimmune and normal mice which are the target molecules for anti-double stranded DNA antibodies. Immunology. 1996;87:362&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1384103</ArticleId><ArticleId IdType="pubmed">8778020</ArticleId></ArticleIdList></Reference><Reference><Citation>Otey C.A., Carpen O. Alpha-actinin revisited: A fresh look at an old player. Cell Motil. Cytoskeleton. 2004;58:104&#x2013;111. doi: 10.1002/cm.20007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cm.20007</ArticleId><ArticleId IdType="pubmed">15083532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Weinstein E., Tuzova M., Davidson A., Mundel P., Marambio P., Putterman C. Cross-reactivity of human lupus anti-DNA antibodies with &#x3b1;-actinin and nephritogenic potential. Arthritis Rheum. 2005;52:522&#x2013;530. doi: 10.1002/art.20862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20862</ArticleId><ArticleId IdType="pubmed">15693007</ArticleId></ArticleIdList></Reference><Reference><Citation>Riboldi P., Gerosa M., Moroni G., Radice A., Allegri F., Sinico A., Tincani A., Meroni P.L. Anti-DNA antibodies: A diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity. 2005;38:39&#x2013;45. doi: 10.1080/08916930400022616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930400022616</ArticleId><ArticleId IdType="pubmed">15804704</ArticleId></ArticleIdList></Reference><Reference><Citation>Devey M.E., Lee S.R., Le Page S., Feldman R., Isenberg D.A. Serial studies of the IgG subclass and functional affinity of DNA antibodies in systemic lupus erythematosus. J. Autoimmun. 1998;1:483&#x2013;494. doi: 10.1016/0896-8411(88)90069-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-8411(88)90069-8</ArticleId><ArticleId IdType="pubmed">3075912</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670&#x2013;673. doi: 10.1126/science.1129594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1129594</ArticleId><ArticleId IdType="pubmed">16888140</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xe4;sermann F., Boerema D.J., R&#xfc;egsegger M., Hofmann A., Wymann S., Zuercher A.W., Miescher S. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS ONE. 2012;7:e37243. doi: 10.1371/journal.pone.0037243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037243</ArticleId><ArticleId IdType="pmc">PMC3366990</ArticleId><ArticleId IdType="pubmed">22675478</ArticleId></ArticleIdList></Reference><Reference><Citation>Otani M., Kuroki A., Kikuchi S., Kihara M., Nakata J., Ito K., Furukawa J.-i. Sialylation determines the nephritogenicity of IgG3 cryoglobulins. J. Am. Soc. Nephrol. 2012;23:1869&#x2013;1878. doi: 10.1681/ASN.2012050477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2012050477</ArticleId><ArticleId IdType="pmc">PMC3482736</ArticleId><ArticleId IdType="pubmed">23024299</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J., Zhou Z., Zhang R., You Y., Guo Z., Huang J., Wang F., Sun Y., Liu H., Cheng X., et al. Fucosylation of anti-dsDNA IgG1 correlates with disease activity of treatment-na&#xef;ve systemic lupus erythematosus patients. eBioMedicine. 2022;77:103883. doi: 10.1016/j.ebiom.2022.103883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103883</ArticleId><ArticleId IdType="pmc">PMC8857559</ArticleId><ArticleId IdType="pubmed">35182998</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou L.-B., Chen C.-C., Chiang W.-Y., Chen M.-H. De-sialylated and sialylated IgG anti-dsDNA antibodies respectively worsen and mitigate experimental mouse lupus proteinuria and possible mechanisms. Int. Immunopharmacol. 2022;109:108837. doi: 10.1016/j.intimp.2022.108837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.108837</ArticleId><ArticleId IdType="pubmed">35640407</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou L.-B., Wang T.-Y., Lui I.-J., Wu H.-C., Ke P.-Y., Fang Y.-F., Chen Y.-F. &#x3b1;-2,6-sialic acid/IgG anti-dsDNA ratios correlate with human lupus disease activity and possible mechanisms: A pilot study. Lupus. 2022;31:927&#x2013;938. doi: 10.1177/09612033221099766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221099766</ArticleId><ArticleId IdType="pubmed">35531921</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.-Y., Yu C.-L., Wu T.-H., Lu J.-Y., Lair T.-S., Tsai Y.-Y., Chou C.-T. Polyclonal anticardiolipin antibodies purified from sera of patients with active systemic lupus erythematosus induce apoptosis of the cultured glomerular mesangial cells. Scand. J. Rheumatol. 2000;29:370&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">11132206</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelzner P., Deliyska B., F&#xfc;nfst&#xfc;ck R., Hein G., Herrmann D., Stein G. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus&#x2014;Relationship with disease activity and renal involvement. Clin. Rheumatol. 2003;22:271&#x2013;278. doi: 10.1007/s10067-003-0724-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-003-0724-3</ArticleId><ArticleId IdType="pubmed">14576989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kianmehr N., Khoshmirsafa M., Shekarabi M., Falak R., Haghighi A., Masoodian M., Seif F., Omidi F., Shirani F., Dadfar N. High frequency of concurrent anti-C1q and anti-dsDNA but not anti-C3b antibodies in patients with lupus nephritis. J. Immunoassay Immunothem. 2021;42:406&#x2013;423. doi: 10.1080/15321819.2021.1895215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15321819.2021.1895215</ArticleId><ArticleId IdType="pubmed">33788670</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaudineau Y., Deocharan B., Jousse S., Renaudineau E., Putterman C., Youinou P. Anti-alpha-actinin antibodies: A new marker of lupus nephritis. Autoimmun. Rev. 2007;6:464&#x2013;468. doi: 10.1016/j.autrev.2007.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2007.02.001</ArticleId><ArticleId IdType="pubmed">17643934</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi S., Adnan E., Ishizaki J., Miyazaki T., Tanaka Y., Matsumoto T., Suemori K., Shudou M., Okura T., Takeda H., et al. Novel autoantigens associated with lupus nephritis. PLoS ONE. 2015;10:e0126564. doi: 10.1371/journal.pone.0126564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0126564</ArticleId><ArticleId IdType="pmc">PMC4476694</ArticleId><ArticleId IdType="pubmed">26098692</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarfaraz S., Anis S., Ahmed E., Muzaffar R. Clinical significance of anti-ribosomal P protein antibodies in patients with lupus nephritis. Rev. Recent Clin. Trials. 2018;13:281&#x2013;286. doi: 10.2174/1574887113666180409154641.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1574887113666180409154641</ArticleId><ArticleId IdType="pubmed">29629666</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakamatsu A., Sato H., Kaneko Y., Cho T., Ito Y., Kurosawa Y., Hasegawa E., Kobayashi D., Nakatsue T., Kuroda T., et al. Association of coexisting anti-ribosomal P and anti-dsDNA antibodies with histology and renal prognosis in lupus nephritis patients. Lupus. 2021;30:448&#x2013;458. doi: 10.1177/0961203320983906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320983906</ArticleId><ArticleId IdType="pubmed">33402038</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang X., Ren L., Sun G., Yu T., Yao Y., Wang L., Liu F., Zhang L., He X., Liu M. Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity. Immun. Inflamm. Dis. 2021;9:407&#x2013;418. doi: 10.1002/iid3.401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.401</ArticleId><ArticleId IdType="pmc">PMC8127563</ArticleId><ArticleId IdType="pubmed">33470559</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman S., Mohan C. Lupus nephritis biomarkers. Clin. Immunol. 2017;185:10&#x2013;20. doi: 10.1016/j.clim.2016.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.08.001</ArticleId><ArticleId IdType="pubmed">27498110</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T., Ding H., Han J., Arriens C., Wei C., Han W., Pedroza C., Jiang S., Anolik J., Petri M., et al. Antibody-array-based proteomic screening of serum markers in systemic lupus erythematosus: A discovery study. J. Proteome. Res. 2016;15:2102&#x2013;2114. doi: 10.1021/acs.jproteome.5b00905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b00905</ArticleId><ArticleId IdType="pmc">PMC5193538</ArticleId><ArticleId IdType="pubmed">27211902</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Duran V., Vanarsa K., Mohan C. Targeted urine proteomics in lupus nephritis&#x2014;A meta-analysis. Expert Rev. Proteom. 2020;17:767&#x2013;776. doi: 10.1080/14789450.2020.1874356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2020.1874356</ArticleId><ArticleId IdType="pubmed">33423575</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzo L., Lindblom J., Mohan C., Parodis I. Current insights on biomarkers in lupus nephritis: A systematic review of the literature. J. Clin. Med. 2022;11:5759. doi: 10.3390/jcm11195759.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11195759</ArticleId><ArticleId IdType="pmc">PMC9570701</ArticleId><ArticleId IdType="pubmed">36233628</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent F.B., Saulep-Easton D., Figgett W.A., Fairfax K.A., Mackay F. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24:203&#x2013;215. doi: 10.1016/j.cytogfr.2013.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2013.04.003</ArticleId><ArticleId IdType="pmc">PMC7108297</ArticleId><ArticleId IdType="pubmed">23684423</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent F.B., Morand E.F., Mackay F. BAFF and innate immunity: New therapeutic targets for systemic lupus erythematosus. Immunol. Cell Biol. 2012;90:293&#x2013;303. doi: 10.1038/icb.2011.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2011.111</ArticleId><ArticleId IdType="pubmed">22231653</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarting A., Relle M., Meineck M., F&#xf6;hr B., Triantafyllias K., Weinmann A., Roth W., Weimann-Menke J. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men. Lupus. 2018;27:243&#x2013;256. doi: 10.1177/0961203317717083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317717083</ArticleId><ArticleId IdType="pubmed">28659046</ArticleId></ArticleIdList></Reference><Reference><Citation>Suso J.P., Posso-Osorio I., Jim&#xe9;nez C.A., Naranjo-Escobar J., Ospina F.E., S&#xe1;nchez A., Ca&#x148;as C.A., Tob&#xf3;n G.J. Profile of BAFF and its receptors&#x2019; expression in lupus nephritis is associated with pathological classes. Lupus. 2018;27:708&#x2013;715. doi: 10.1177/0961203317739132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317739132</ArticleId><ArticleId IdType="pubmed">29087261</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Valencia D., R&#xed;os-Serna L.J., Posso-Osorio I., Naranjo-Escobar J., L&#xf3;pez D., Bedoya-Joaqui V., Nieto-Aristiz&#xe1;bal I., Castro A.M., Di&#xe1;z-Ordo&#x148;ez L., Navarro E.P., et al. Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers. J. Transl. Autoimmun. 2019;3:100027. doi: 10.1016/j.jtauto.2019.100027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2019.100027</ArticleId><ArticleId IdType="pmc">PMC7388398</ArticleId><ArticleId IdType="pubmed">32743512</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed;n-Rosales M., Palafox-S&#xe1;nchez C.A., Franco-Topete R.A., Carrillo-Ballesteros F.J., Cruz A., Salazar-Camarena D.C., Mu&#x148;oz-Valle J.F., Ramos-Solano F. Renal tissue expression of BAFF and BAFF receptors is associated with proliferative lupus nephritis. J. Clin. Med. 2022;12:71. doi: 10.3390/jcm12010071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12010071</ArticleId><ArticleId IdType="pmc">PMC9821186</ArticleId><ArticleId IdType="pubmed">36614872</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vilet J.M., Parikh S.V., Song H., Fadda P., Shapiro J.P., Ayoub I., Yu L., Zhang J., Uribe-Uribe N., Rovin B.H. Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at a renal flare. Nephrol. Dial. Transplant. 2019;34:1197&#x2013;1206. doi: 10.1093/ndt/gfy125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfy125</ArticleId><ArticleId IdType="pmc">PMC7967887</ArticleId><ArticleId IdType="pubmed">29800348</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairhurst A.-M., Xie C., Fu Y., Wang A., Boudreaux C., Zhou X.J., Cibotti R., Coyle A., Connolly J.E., Wakeland E.K., et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J. Immuol. 2009;183:6831&#x2013;6838. doi: 10.4049/jimmunol.0900742.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900742</ArticleId><ArticleId IdType="pmc">PMC2876821</ArticleId><ArticleId IdType="pubmed">19864599</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakkim A., F&#xfc;rnrohr B.G., Amann K., Laube B., Abed U.A., Brinkmann V., Herrmann M., Voll R.E., Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA. 2010;107:9813&#x2013;9818. doi: 10.1073/pnas.0909927107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909927107</ArticleId><ArticleId IdType="pmc">PMC2906830</ArticleId><ArticleId IdType="pubmed">20439745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X., Ren Y., He X. IFN-1 mediates lupus nephritis from the beginning to renal fibrosis. Front. Immunol. 2021;12:676082. doi: 10.3389/fimmu.2021.676082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676082</ArticleId><ArticleId IdType="pmc">PMC8093624</ArticleId><ArticleId IdType="pubmed">33959133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavragani C.P., Kirou K.A., Seshan S.V., Crow M.K. Type 1 interferon and neutrophil transcripts in lupus nephritis renal biopsies: Clinical and histopathological association. Rheumatology. 2022:1&#x2013;5. doi: 10.1093/rheumatology/keac641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac641</ArticleId><ArticleId IdType="pubmed">36355567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Yang Z., Yu H., Lin W., Wu R., Yang H., Yang K. Predicting diagnostic gene expression profiles associated with immune infiltration in patients with lupus nephritis. Front. Immunol. 2022;13:839197. doi: 10.3389/fimmu.2022.839197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.839197</ArticleId><ArticleId IdType="pmc">PMC9755505</ArticleId><ArticleId IdType="pubmed">36532018</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmore A.C., Wilson H.R., Cairns T.D., Botto M., Lightstone L., Bruce I.N., Cook H.T., Pickering M.C. Immune gene expression and functional networks in distinct lupus nephritis. Lupus Sci. Med. 2022;9:e000615. doi: 10.1136/lupus-2021-000615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000615</ArticleId><ArticleId IdType="pmc">PMC8788334</ArticleId><ArticleId IdType="pubmed">35074933</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh S., Malvar A., Song H., Shapiro J., Mejia-Vilet J.M., Ayoub I., Almaani S., Madhavan S., Alberton V., Besso C., et al. Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis. Kidney Int. 2022;102:845&#x2013;865. doi: 10.1016/j.kint.2022.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.05.033</ArticleId><ArticleId IdType="pmc">PMC9613357</ArticleId><ArticleId IdType="pubmed">35788359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammad A.M., Youssef H.M., El-Arman M.M. Transforming growth factor beta 1 in children with systemic lupus erythematosus: A possible relation with clinical presentation of lupus nephritis. Lupus. 2006;15:608&#x2013;612. doi: 10.1177/0961203306071873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306071873</ArticleId><ArticleId IdType="pubmed">17080918</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan R.W.-Y., Tam L.-S., Li E.K.-M., Lai F.M.-M., Chow K.-M., Lai K.-B., Li P.K.-T., Szeto C.-C. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 2003;48:1326&#x2013;1331. doi: 10.1002/art.11062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.11062</ArticleId><ArticleId IdType="pubmed">12746905</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin B.H., Song H., Birmingham D.J., Hebert L.A., Yu C.Y., Nagaraja H.N. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 2005;16:467&#x2013;473. doi: 10.1681/ASN.2004080658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2004080658</ArticleId><ArticleId IdType="pubmed">15601744</ArticleId></ArticleIdList></Reference><Reference><Citation>Avihingsanon Y., Phumesin P., Benjachat T., Akkasilpa S., Killikowit V., Praditpomsilpa K., Wongpiyabavorn J., Eiam-Ong S., Hemachudha T., Tungsanga K., et al. Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis. Kidney Int. 2006;69:747&#x2013;753. doi: 10.1038/sj.ki.5000132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5000132</ArticleId><ArticleId IdType="pubmed">16518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz N., Rubinstein T., Burkly L.C., Collins C.E., Blanco I., Su L., Hojaili B., Mackay M., Aranow C., Stohl W., et al. Urinary TWEAK as a biomarker of lupus nephritis: A multicenter cohort study. Arthritis Res. Ther. 2009;11:R143. doi: 10.1186/ar2816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2816</ArticleId><ArticleId IdType="pmc">PMC2787265</ArticleId><ArticleId IdType="pubmed">19785730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T., Xie C., Wang H.W., Zhou X.J., Schwartz N., Calixto S., Mackay M., Aranow C., Putterman C., Mohan C. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 2007;179:7166&#x2013;7175. doi: 10.4049/jimmunol.179.10.7166.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.10.7166</ArticleId><ArticleId IdType="pubmed">17982109</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolignano D., Donato V., Coppolino G., Campo S., Buemi A., Lacquaniti A., Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am. J. Kidney Dis. 2008;52:595&#x2013;605. doi: 10.1053/j.ajkd.2008.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2008.01.020</ArticleId><ArticleId IdType="pubmed">18725016</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein T., Pitashny M., Putterman C. The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/lipocalin -2 as a biomarker of lupus nephritis. Autoimmun. Rev. 2008;7:229&#x2013;234. doi: 10.1016/j.autrev.2007.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2007.11.013</ArticleId><ArticleId IdType="pubmed">18190883</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.-C., Hsieh S.-C., Li K.-J., Wu C.-H., Lu M.-C., Tsai C.-Y., Yu C.-L. Urinary neutrophil gelatinase-associated lipocalin is a potential biomarker for renal damage in patients with systemic lupus erythematosus. J. Biomed. Biotechnol. 2012;2012:759313. doi: 10.1155/2012/759313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/759313</ArticleId><ArticleId IdType="pmc">PMC3303691</ArticleId><ArticleId IdType="pubmed">22500106</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh S.-C., Tsai C.-Y., Yu C.-L. Potential serum and urine biomarkers in patients with lupus nephritis and the unsolved problems. Open Access Rheumatol. 2016;8:81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5098719</ArticleId><ArticleId IdType="pubmed">27843374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T.-H., Li K.-J., Yu C.-L., Tsai C.-Y. Tamm-Horsfall protein is a potent immunomodulatory molecule and a disease biomarker in the urinary system. Molecules. 2018;23:200. doi: 10.3390/molecules23010200.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23010200</ArticleId><ArticleId IdType="pmc">PMC6017547</ArticleId><ArticleId IdType="pubmed">29361765</ArticleId></ArticleIdList></Reference><Reference><Citation>Badr A.M.M., Farag Y., Abdelshafy M., Riad N.M. Urinary interleukin 22 binding protein as a marker of lupus nephritis in Egyptian children with juvenile systemic lupus erythematosus. Clin. Rheumatol. 2018;37:451&#x2013;458. doi: 10.1007/s10067-017-3812-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-017-3812-5</ArticleId><ArticleId IdType="pubmed">28887660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertolo M., Baumgart S., Durek P., Peddinghaus A., Mei H., Rose T., Enghard P., Cr&#xfc;tzkau A. Deep phenotyping of urinary leukocytes by mass cytometry reveals a leukocyte signature for early and non-invasive prediction of response to treatment in active lupus nephritis. Front. Immunol. 2020;11:256. doi: 10.3389/fimmu.2020.00256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00256</ArticleId><ArticleId IdType="pmc">PMC7105605</ArticleId><ArticleId IdType="pubmed">32265898</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A., Rao D.A., Mohan C., Zhang T., Rosenberg A., Fenaroli P., Belmont H.M., Izmirly P., Clancy R., Trujillo J.M., et al. Urine proteomics and renal single-cell transcriptomics implicate interkeukine-16 in lupus nephritis. Arthritis Rheumatol. 2022;74:829&#x2013;839. doi: 10.1002/art.42023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42023</ArticleId><ArticleId IdType="pmc">PMC9050800</ArticleId><ArticleId IdType="pubmed">34783463</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbano C., G&#xf3;mez-Puerta J.A., Mu&#xf1;oz-Vahos C., Vanegas-Garc&#xed;a A., Rajas M., V&#xe1;squez G., Casta&#xf1;o D. HMGB1+ microparticles present in urine are hallmarks of nephritis in patients with systemic lupus erythematosus. Eur. J. Immunol. 2019;49:323&#x2013;335. doi: 10.1002/eji.201847747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847747</ArticleId><ArticleId IdType="pubmed">30537116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., Hu Z.B., Chen P.P., Lu C.C., Zhang J.X., Li X.Q., Yuan B.Y., Huang S.J., Ma K.L. Urinary podocyte microparticles are associated with disease activity and renal injury in systemic lupus erythematosus. BMC Nephrol. 2019;20:303. doi: 10.1186/s12882-019-1482-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-019-1482-z</ArticleId><ArticleId IdType="pmc">PMC6683479</ArticleId><ArticleId IdType="pubmed">31382919</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudehithlu K.P., Hart P., Joshi A., Garcia-Gomez I., Cimbaluk D.J., Dunea G., Arruda J.A.L., Singh A.K. Urine exosomal ceruloplasmin: A potential early biomarker of underlying kidney disease. Clin. Exp. Nephrol. 2019;23:1013&#x2013;1021. doi: 10.1007/s10157-019-01734-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-019-01734-5</ArticleId><ArticleId IdType="pubmed">30955187</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9; C., Cort&#xe9;s-Hern&#xe1;ndez J., Felip M.L., Vidal M., Ordi-Ros J. miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. Nephrol. Dial. Transplant. 2015;30:1488&#x2013;1496. doi: 10.1093/ndt/gfv128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfv128</ArticleId><ArticleId IdType="pubmed">26040904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9; C., Molin&#xe9; T., Vidal M., Ordi-Ros J., Cort&#xe9;s-Hern&#xe1;ndez J. An exosomal urinary miRNA signature for early diagnosis of renal fibrosis in lupus nephritis. Cells. 2019;8:773. doi: 10.3390/cells8080773.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8080773</ArticleId><ArticleId IdType="pmc">PMC6721515</ArticleId><ArticleId IdType="pubmed">31349698</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangtanatakul P., Klinchanhom S., Sodsai P., Sutichet T., Promjeen C., Avihingsanon Y., Hirankarn N. Down-regulation of let-7a and miR-21 in urine exosomes from lupus nephritis patients during disease flare. Asian Pac. J. Allergy Immunol. 2019;37:189&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">30118248</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Vives E., Sol&#xe9; C., Molin&#xe9; T., Vidal M., Agraz I., Ordi-Ros J., Cort&#xe9;s-Hern&#xe1;ndez J. The urinary exosomal miRNA expression profile is predictive of clinical response in lupus nephritis. Int. J. Mol. Sci. 2020;21:1372. doi: 10.3390/ijms21041372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21041372</ArticleId><ArticleId IdType="pmc">PMC7073236</ArticleId><ArticleId IdType="pubmed">32085620</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Hernandez J., Martinez-Arroyo O., Ortega A., Galera M., Solis-Salguero M.A., Chaves F.J., Redon J., Forner M.J., Cortes R. Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis. J. Nephrol. 2021;34:1157&#x2013;1167. doi: 10.1007/s40620-020-00832-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-020-00832-y</ArticleId><ArticleId IdType="pubmed">32803682</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C., Guo F., Yang H., Ma J., Li H., Yin L., Li M., Liu S. Identification and analysis of the predictive urinary exosomal miR-195-5p in lupus nephritis based on renal miRNA-mRNA co-expression network. Lupus. 2022;31:1786&#x2013;1799. doi: 10.1177/09612033221133684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221133684</ArticleId><ArticleId IdType="pubmed">36223498</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Zhang X., Meng K., Sun Y., Shu R., Han Y., Feng Q., Li Z., Yang P., Liang J. Urinary exosome tsRNAs as novel markers for diagnosis and prediction of lupus nephritis. Front. Immunol. 2023;14:1077645. doi: 10.3389/fimmu.2023.1077645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1077645</ArticleId><ArticleId IdType="pmc">PMC9946979</ArticleId><ArticleId IdType="pubmed">36845141</ArticleId></ArticleIdList></Reference><Reference><Citation>Arag&#xf3;n C.C., Taf&#xfa;r R.-A., Su&#xe1;rez-Avellaneda A., Mart&#xed;nez M.T., de las Salas A., Tob&#xf3;n G.J. Urinary biomarkers in lupus nephritis. J. Transl. Autoimmun. 2020;3:100042. doi: 10.1016/j.jtauto.2020.100042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2020.100042</ArticleId><ArticleId IdType="pmc">PMC7388339</ArticleId><ArticleId IdType="pubmed">32743523</ArticleId></ArticleIdList></Reference><Reference><Citation>Morell M., P&#xe9;rez-C&#xf3;zar F., Mara&#x148;&#xf3;n C. Immune-related urine biomarkers for the diagnosis of lupus nephritis. Int. J. Mol. Sci. 2021;22:7143. doi: 10.3390/ijms22137143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22137143</ArticleId><ArticleId IdType="pmc">PMC8267641</ArticleId><ArticleId IdType="pubmed">34281193</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap D.Y.H., Mok C.C. Novel and emerging treatment strategies for lupus nephritis. Expert Rev. Clin. Pharmacol. 2022;15:1283&#x2013;1292. doi: 10.1080/17512433.2022.2138340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2022.2138340</ArticleId><ArticleId IdType="pubmed">36260817</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I., Gomez A., Lindblom J., Chow J.W., Sj&#xf6;wall C., Sciascia S., Gatto M. B cell kinetics upon therapy commencement for active extrarenal systemic lupus erythematosus in relation to development of renal flares: Results from three phase III clinical trials of belimumab. Int. J. Mol. Sci. 2022;23:13941. doi: 10.3390/ijms232213941.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232213941</ArticleId><ArticleId IdType="pmc">PMC9698874</ArticleId><ArticleId IdType="pubmed">36430417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vilet J.M., Malvar A., Arazi A., Rovin B.H. The lupus nephritis management renaissance. Kidney Int. 2022;101:242&#x2013;255. doi: 10.1016/j.kint.2021.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.09.012</ArticleId><ArticleId IdType="pubmed">34619230</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuichi K., Wada T., Iwata Y., Sakai N., Yoshimoto K., Shimizu M., Kobayashi K., Takasawa K., Kida H., Takeda S., et al. Upregulation of fractalkine in human crescentic glomerulonephritis. Nephron. 2001;87:314&#x2013;320. doi: 10.1159/000045936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000045936</ArticleId><ArticleId IdType="pubmed">11287774</ArticleId></ArticleIdList></Reference><Reference><Citation>Segerer S., Hughes E., Hudkins K.L., Mack M., Goodpaster T., Alpers C.E. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int. 2002;62:488&#x2013;495. doi: 10.1046/j.1523-1755.2002.00480.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2002.00480.x</ArticleId><ArticleId IdType="pubmed">12110009</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., Schall T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640&#x2013;644. doi: 10.1038/385640a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/385640a0</ArticleId><ArticleId IdType="pubmed">9024663</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue A., Hasegawa H., Kohno M., Ito M.R., Terada M., Imai T., Yoshie O., Nose M., Fujita S. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 2005;52:1522&#x2013;1533. doi: 10.1002/art.21007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21007</ArticleId><ArticleId IdType="pubmed">15880599</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Xu W., Zhou R. NLRP3 inflammasome activation and cell death. Cell. Mol. Immunol. 2021;18:2114&#x2013;2127. doi: 10.1038/s41423-021-00740-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00740-6</ArticleId><ArticleId IdType="pmc">PMC8429580</ArticleId><ArticleId IdType="pubmed">34321623</ArticleId></ArticleIdList></Reference><Reference><Citation>Su B., Ye H., You X., Ni H., Chen X., Li L. Icariin alleviates murine lupus nephritis via inhibiting NF-&#x3ba;B activation pathway and NLRP3 inflammasome. Life Sci. 2018;208:26&#x2013;32. doi: 10.1016/j.lfs.2018.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2018.07.009</ArticleId><ArticleId IdType="pubmed">30146016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Ai L., Sun Y., Yang B., Chen S., Wang Q., Kuang H. Role of NLPR3 inflammasome in lupus nephritis and therapeutic targeting by phytochemicals. Front. Pharmacol. 2021;12:621300. doi: 10.3389/fphar.2021.621300.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.621300</ArticleId><ArticleId IdType="pmc">PMC8417800</ArticleId><ArticleId IdType="pubmed">34489689</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z., Zhang S., Wu P., Ren Q., Wei P., Hong M., Feng Y., Wong C.K., Tang H., Zeng H. A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis. Clin. Transl. Med. 2021;11:e309. doi: 10.1002/ctm2.309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.309</ArticleId><ArticleId IdType="pmc">PMC7851357</ArticleId><ArticleId IdType="pubmed">33634995</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D., Li Y., Shi X., Yao M., Wu D., Zheng Y., Lin Q., Yang Y. Transcriptional expression of CXCL10 and STAT1 in lupus nephritis and the intervention effect of triptolide. Clin. Rheumatol. 2023;42:539&#x2013;548. doi: 10.1007/s10067-022-06400-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06400-y</ArticleId><ArticleId IdType="pmc">PMC9873713</ArticleId><ArticleId IdType="pubmed">36374433</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang D., Mai H., Ruan F., Fu H. The efficacy of triptolide in preventing diabetic kidney diseases: A systematic review and meta-analysis. Front. Pharmacol. 2021;12:728758. doi: 10.3389/fphar.2021.728758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.728758</ArticleId><ArticleId IdType="pmc">PMC8517526</ArticleId><ArticleId IdType="pubmed">34658869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Guo S., Niu F., Liu D., Zhuang Y. Complement 1q protects MRL/lpr mice against lupus nephritis via inhibiting the nuclear factor-kB pathway. Mol. Med. Rep. 2020;22:5436&#x2013;5443. doi: 10.3892/mmr.2020.11588.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11588</ArticleId><ArticleId IdType="pubmed">33173997</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K., Deng Y., Shang S., Tang L., Li Q., Bai X., Chen X. Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice. Biomed. Pharmacother. 2022;153:113433. doi: 10.1016/j.biopha.2022.113433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113433</ArticleId><ArticleId IdType="pubmed">36076550</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Q., Gao C., Chen Y., Feng Y., Liu W.J., Liu H.-F. Update on the role of autophagy in systemic lupus erythematosus: A novel therapeutic target. Biomed. Pharmacother. 2015;71:190&#x2013;193. doi: 10.1016/j.biopha.2015.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2015.02.017</ArticleId><ArticleId IdType="pubmed">25960235</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartleben B., G&#xf6;del M., Meyer-Schwesinger C., Liu S., Ulrich T., K&#xf6;bler S., Wiech T., Grahammer F., Arnold S.J., Lindenmeyer M.T., et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Investig. 2010;120:1084&#x2013;1096. doi: 10.1172/JCI39492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI39492</ArticleId><ArticleId IdType="pmc">PMC2846040</ArticleId><ArticleId IdType="pubmed">20200449</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros F., Muller S. Pharmacological regulators of autophagy and their link with modulators of lupus disease. Br. J. Pharmacol. 2014;171:4337&#x2013;4359. doi: 10.1111/bph.12792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12792</ArticleId><ArticleId IdType="pmc">PMC4209143</ArticleId><ArticleId IdType="pubmed">24902607</ArticleId></ArticleIdList></Reference><Reference><Citation>Stylianou K., Petrakis I., Mavroeidi V., Stratakis S., Vardaki E., Perakis K., Stratigis S., Passam A., Papadogiorgaki E., Giannakakis K., et al. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. Nephrol. Dial. Transplant. 2011;26:498&#x2013;508. doi: 10.1093/ndt/gfq496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfq496</ArticleId><ArticleId IdType="pubmed">20709738</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y.-Y., Zhou X.-J., Cheng F.-J., Hou P., Ren Y.-L., Wang S.-X., Zhao M.-H., Yang L., Mart&#xed;nez J., Zhang H. Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-&#x3b1; in lupus nephritis. Ann. Rheum. Dis. 2018;77:1799&#x2013;1809. doi: 10.1136/annrheumdis-2018-213028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213028</ArticleId><ArticleId IdType="pmc">PMC6800572</ArticleId><ArticleId IdType="pubmed">30209031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.H., Roberts C.W.M. Targeting EZH2 in cancer. Nat. Med. 2016;22:128&#x2013;134. doi: 10.1038/nm.4036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4036</ArticleId><ArticleId IdType="pmc">PMC4918227</ArticleId><ArticleId IdType="pubmed">26845405</ArticleId></ArticleIdList></Reference><Reference><Citation>Coit P., Dozmorov M.G., Merrill J.T., McCune W.J., Maksimowicz-McKinnon K., Wren J.D., Sawalha A.H. Epigenetic reprogramming in naive CD4+ T cells favoring cell activation and non-Th1 effector T cell immune responses as an early event in lupus flares. Arthritis Rheumatol. 2016;68:2200&#x2013;2209. doi: 10.1002/art.39720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39720</ArticleId><ArticleId IdType="pmc">PMC5001909</ArticleId><ArticleId IdType="pubmed">27111767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E., Kim M., Woo D.-H., Shin Y., Shin J., Chang N., Oh Y.T., Kim H., Rheey J., Nakano I., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23:839&#x2013;852. doi: 10.1016/j.ccr.2013.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2013.04.008</ArticleId><ArticleId IdType="pmc">PMC4109796</ArticleId><ArticleId IdType="pubmed">23684459</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Iwata S., Hajime M., Ohkubo N., Todoroki Y., Miyata H., Ueno M., Hao H., Zhang T., Fan J., et al. Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase EZH2. Arthritis Rheumatol. 2020;72:1143&#x2013;1153. doi: 10.1002/art.41208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41208</ArticleId><ArticleId IdType="pubmed">31961063</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Jiang X., Qi C., Zhang C., Qu B., Shen N. EZH2 inhibition interferes with the activation of type I interferon signaling pathway and ameliorates lupus nephritis in NZB/NZW F1 mice. Front. Immunol. 2021;12:653989. doi: 10.3389/fimmu.2021.653989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.653989</ArticleId><ArticleId IdType="pmc">PMC8044841</ArticleId><ArticleId IdType="pubmed">33868295</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 2010;79:351&#x2013;379. doi: 10.1146/annurev-biochem-060308-103103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-060308-103103</ArticleId><ArticleId IdType="pubmed">20533884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.-Y., Shen C.-Y., Liu C.-W., Hsieh S.-C., Liao H.-T., Li K.-J., Lu C.-S., Lee H.-T., Lin C.-S., Wu C.-H., et al. Aberrant non-coding RNA expression in patients with systemic lupus erythematosus: Consequences for immune dysfunctions and tissue damage. Biomolecules. 2020;10:1641. doi: 10.3390/biom10121641.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10121641</ArticleId><ArticleId IdType="pmc">PMC7762297</ArticleId><ArticleId IdType="pubmed">33291347</ArticleId></ArticleIdList></Reference><Reference><Citation>So B.Y.F., Yap D.Y.H., Chan T.M. MicroRNAs in lupus nephritis- role in disease pathogenesis and clinical applications. Int. J. Mol. Sci. 2021;22:10737. doi: 10.3390/ijms221910737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910737</ArticleId><ArticleId IdType="pmc">PMC8509214</ArticleId><ArticleId IdType="pubmed">34639078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihaylova G., Vasilev V., Kosturkova M.B., Stoyanov G.S., Radanova M. Long non-coding RNAs as new biomarkers in lupus nephritis: A connection between present and future. Cureus. 2020;12:e9003. doi: 10.7759/cureus.9003.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.9003</ArticleId><ArticleId IdType="pmc">PMC7402529</ArticleId><ArticleId IdType="pubmed">32775083</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang H., Liu Q. The role of non-coding RNA in lupus nephritis. Hum. Cell. 2023;36:923&#x2013;936. doi: 10.1007/s13577-023-00883-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-023-00883-w</ArticleId><ArticleId IdType="pubmed">36840837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R.F., Shaker O.G., Abdelghany H.M., Abdallah N.H., Elsayed S.H., Kamel B.A. Role of micro-RNA 132 and its long non-coding SOX2 in diagnosis of lupus nephritis. Lupus. 2022;31:89&#x2013;96. doi: 10.1177/09612033211067166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211067166</ArticleId><ArticleId IdType="pubmed">35019799</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitner F., Westerhuis R., Burg M., Weinhold B., Gr&#xf6;ne H.J., Ostendorf T., R&#xfc;ther U., Koch K.M., Rees A.J., Floege J. Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int. 1997;51:69&#x2013;78. doi: 10.1038/ki.1997.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1997.9</ArticleId><ArticleId IdType="pubmed">8995719</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun H.-Y., Chung J.-W., Kim H.-A., Yun J.-M., Jeon J.-Y., Ye Y.-M., Kim S.-H., Park H.-S., Suh C.-H. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 2007;27:461&#x2013;466. doi: 10.1007/s10875-007-9104-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-007-9104-0</ArticleId><ArticleId IdType="pubmed">17587156</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Zhang N., Zhang J., Zhao H., Wang X. miR-410 suppresses the expression of interleukin-6 as well as renal fibrosis in the pathogenesis of lupus nephritis. Clin. Exp. Pharmacol. Physiol. 2016;43:616&#x2013;625. doi: 10.1111/1440-1681.12576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1440-1681.12576</ArticleId><ArticleId IdType="pubmed">27028192</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob N., Yang H., Pricop L., Liu Y., Gao X., Zheng S.G., Wang J., Gao H.-X., Putterman C., Koss M.N., et al. Accelerated pathological and clinical nephritis in system lupus erythematosus-prone New Zealand mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J. Immunol. 2009;182:2532&#x2013;2541. doi: 10.4049/jimmunol.0802948.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0802948</ArticleId><ArticleId IdType="pmc">PMC2790862</ArticleId><ArticleId IdType="pubmed">19201910</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Peng W., Ouyang X., Li W., Dai Y. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl. Res. 2012;160:198&#x2013;206. doi: 10.1016/j.trsl.2012.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2012.04.002</ArticleId><ArticleId IdType="pubmed">22683424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen X., Deng Y. miR-125a-3p decreases levels of interleukin-17 and suppresses renal fibrosis via down-regulating TGF-&#x3b2;1 in systemic lupus erythematosus mediated lupus nephritic mice. Am. J. Transl. Res. 2019;11:1843&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6456516</ArticleId><ArticleId IdType="pubmed">30972208</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L., Leonard D. Interferon pathway in SLE: One key to unlocking the mystery of the disease. Lupus Sci. Med. 2019;6:e000270. doi: 10.1136/lupus-2018-000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000270</ArticleId><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Han X., Jiang X., Ding H., Qi C., Yin Z., Xiao J., Xiong L., Guo Q., Ye Z., et al. Downregulation of renal Hsa-miR-127-3p contributes to the overactivation of type I interferon signaling pathway in the kidney of lupus nephritis. Front. Immunol. 2021;12:747616. doi: 10.3389/fimmu.2021.747616.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.747616</ArticleId><ArticleId IdType="pmc">PMC8566726</ArticleId><ArticleId IdType="pubmed">34745118</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke J., Amann K., Cavagna L., Blettner M., Weinmann A., Schwarting A., Kelley V.R. Colony-stimulating factor-1: A potential biomarker for lupus nephritis. J. Am. Soc. Nephrol. 2015;26:379&#x2013;389. doi: 10.1681/ASN.2013121356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2013121356</ArticleId><ArticleId IdType="pmc">PMC4310658</ArticleId><ArticleId IdType="pubmed">25012167</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom R.D., Florquin S., Singer G.G., Brennan D.C., Kelley V.R. Colony stimulating factor-1 in the induction of lupus nephritis. Kidney Int. 1993;43:1000&#x2013;1009. doi: 10.1038/ki.1993.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1993.141</ArticleId><ArticleId IdType="pubmed">8510378</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W., He X.-J., Zhang W., Chen Y.-L., Yang J., Xiang W., Ding Y. MiR-145 participates in the development of lupus nephritis by targeting CSF1 to regulate the JAK/STAT signaling pathway. Cytokine. 2022;154:155877. doi: 10.1016/j.cyto.2022.155877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2022.155877</ArticleId><ArticleId IdType="pubmed">35468468</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Zhang F., Ma J., Zhang X., Wu L., Qu B., Xia S., Chen S., Tang Y., Shen N. Association of large intergenic non-coding RNA expression with disease activity and organ damage in systemic lupus erythematosus. Arthritis Res. Ther. 2015;17:131. doi: 10.1186/s13075-015-0632-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0632-3</ArticleId><ArticleId IdType="pmc">PMC4440330</ArticleId><ArticleId IdType="pubmed">25994030</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Z., Ye Z., Xue Z., Wu L., Ouyang Y., Yao C., Cui C., Xu N., Ma J., Hu G., et al. Identification of renal long non-coding RNA RP11-2B6.2 as a positive regulator of type I interferon signaling pathway in lupus nephritis. Front. Immunol. 2019;10:975. doi: 10.3389/fimmu.2019.00975.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00975</ArticleId><ArticleId IdType="pmc">PMC6509587</ArticleId><ArticleId IdType="pubmed">31130957</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X., Tang X., Wang S. Roles of circRNAs in autoimmune diseases. Front. Immunol. 2019;10:639. doi: 10.3389/fimmu.2019.00639.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00639</ArticleId><ArticleId IdType="pmc">PMC6454857</ArticleId><ArticleId IdType="pubmed">31001261</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z.-Q., Ding Y., Huang X.-Y., Xiang W., He X.-J. CircELK4 contributes to lupus nephritis by acting as a miR-27b-3p sponge to regulate STING/IRF3/IFN-I signaling. Inflammation. 2021;44:2106&#x2013;2119. doi: 10.1007/s10753-021-01487-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-021-01487-y</ArticleId><ArticleId IdType="pubmed">34091806</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H., Hasni S.A., Perez P., Tandon M., Jang S.-I., Zheng C., Kopp J.B., Austin H., 3rd, Balow J.E., Alevizos I., et al. miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1. J. Am. Soc. Nephrol. 2013;24:1073&#x2013;1087. doi: 10.1681/ASN.2012080849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2012080849</ArticleId><ArticleId IdType="pmc">PMC3699828</ArticleId><ArticleId IdType="pubmed">23723424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M., Wang C., Yuan Y., Zhu Y., Yin Z., Xia Z., Zhang C. Differentially expressed microRNAs in kidney biopsies from various subtypes of nephrotic children. Exp. Mol. Pathol. 2015;99:590&#x2013;595. doi: 10.1016/j.yexmp.2015.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2015.10.003</ArticleId><ArticleId IdType="pubmed">26481277</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Craenenbroeck A.H., Van Craenenbroeck E.M., Van Ackeren K., Hoymans V.Y., Verpooten G.A., Vrints C.J. Impaired vascular function contributes to exercise intolerance in chronic kidney disease. Nephrol. Dial. Transplant. 2016;31:2064&#x2013;2072. doi: 10.1093/ndt/gfw303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfw303</ArticleId><ArticleId IdType="pubmed">27540045</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Fu B., Chen D., Hong Q., Cui J., Li J., Bai X., Chen X. miR-184 and miR-150 promote renal glomerular mesangial cell aging by targeting Rab1a and Rab31. Exp. Cell Res. 2015;336:192&#x2013;203. doi: 10.1016/j.yexcr.2015.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2015.07.006</ArticleId><ArticleId IdType="pubmed">26165933</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan J., Fu J., Chen C., Jiao C., Kong W., Zhang Y., Chang Q., Wang Y., Li D., Illei G.G., et al. LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration. Arthritis Res. Ther. 2019;21:276. doi: 10.1186/s13075-019-2044-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-2044-2</ArticleId><ArticleId IdType="pmc">PMC6907329</ArticleId><ArticleId IdType="pubmed">31829247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao X., Luan J., Jiao C., Ma C., Feng Z., Zhu L., Zhang Y., Fu J., Lai E., Zhang B., et al. LNA-anti-miR-150 alleviates renal interstitial fibrosis by reducing pro-inflammatory M1/M2 macrophage polarization. Front. Immunol. 2022;13:913007. doi: 10.3389/fimmu.2022.913007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.913007</ArticleId><ArticleId IdType="pmc">PMC9389080</ArticleId><ArticleId IdType="pubmed">35990680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>